Health Canada grants approval for Lupin's Rymti biosimilar etanercept

13 Sep 2022 , 03:08 PM

Lupin Limited (Lupin) announced that Rymti, its biosimilar to Enbrel (etanercept), has been approved for use in Canada by Health Canada.

Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis, and pediatric plaque psoriasis are all indications for Rymti.

“Rymti approval is a critical first step for Lupin’s biosimilar franchise in Canada,” said Sofia Mumtaz, President – Legal & Compliance for Canada, Australia, and Japan.

He added, “We believe biosimilars will increase access to excellent therapy for Canadians while lowering healthcare expenditures.”

Lupin is dedicated to increasing patient access to high-quality, life-improving biosimilars.

At around 3.12 PM, Lupin was trading at Rs673.80 up by 0.34% from its previous closing of Rs671.55 on the BSE. The scrip touched intraday high and low of Rs674.80 and Rs668.85 respectively.

For feedback and suggestions, write to us at [e-mail]